Cystic Fibrosis

Cystic Fibrosis (CF) is a life-shortening, autosomal recessive genetic disorder characterized by the production of abnormally thick, sticky mucus. This secretion impairs the function of exocrine glands, leading to multisystem pathology, primarily involving the respiratory, digestive, and reproductive systems.

CF is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene located on chromosome

1. Inheritance follows an autosomal recessive pattern. Environmental factors do not cause the disease but significantly influence the severity of respiratory exacerbations.

The CFTR protein functions as a chloride channel on epithelial cell surfaces. Mutations result in defective chloride transport, leading to dehydrated, viscid secretions. In the lungs, this leads to impaired mucociliary clearance and chronic bacterial infection. In the pancreas, ductal obstruction causes malabsorption of nutrients and pancreatic insufficiency.

CF is most prevalent in individuals of Northern European descent (approximately 1 in 2,500 to 3,500 newborns). It affects males and females equally, with a median survival age now exceeding 40 years due to advanced medical management.

• Family history of CF
• Both parents carrying the CFTR mutation
• Caucasian ethnicity

A. Early Symptoms

• Failure to thrive


• Meconium ileus at birth


• Salty-tasting skin B. Common Symptoms


• Chronic cough with thick sputum


• Recurrent lung infections


• Steatorrhea (fatty stools)


• Abdominal distension C. Advanced Symptoms


• Digital clubbing


• Chronic hypoxia


• Liver cirrhosis


• Diabetes mellitus D. Emergency Symptoms


• Hemoptysis (massive)


• Pneumothorax


• Severe respiratory failure

• Vital signs: Tachypnea, tachycardia.
• Inspection: Barrel chest, digital clubbing, cyanosis.
• Auscultation: Crackles, wheezing, diminished breath sounds.
• Palpation: Hepatomegaly or abdominal masses.

A. Clinical Assessment: History of failure to thrive or chronic respiratory symptoms.
B. Laboratory Testing: Sweat chloride test (gold standard).
C. Imaging Studies: Chest X-ray/CT for lung damage.
D. Functional Tests: Spirometry (FEV1).
E. Biopsy Findings: Not routinely performed.
F. Genetic Testing: CFTR mutation panel.
G. Differential Diagnosis: Primary ciliary dyskinesia, asthma.

Sweat Chloride Test
Type: Sweat induction
Purpose: Diagnosis of CF
Expected Findings: >60 mmol/L
Interpretation: Confirms CF diagnosis

High-Resolution CT (HRCT): Used to assess bronchiectasis and structural lung damage. Vital for monitoring disease progression.

• Primary Ciliary Dyskinesia: Similar respiratory symptoms without pancreatic involvement.
• Asthma: Reversible airway obstruction.

Bronchiectasis, CF-related diabetes, osteoporosis, liver disease, and malnutrition.

A. Lifestyle Modifications: High-calorie diet, hydration.
B. Preventive Measures: Annual influenza vaccine.
C. Medical Treatment:

• CFTR Modulators: Ivacaftor (corrects protein function).


• Mucolytics: Dornase alfa (thins mucus).


• Antibiotics: Tobramycin (for chronic Pseudomonas).

Prognosis has improved significantly; most patients survive into their 40s or 50s with aggressive, multidisciplinary care.

Genetic screening of prospective parents; newborn screening programs.

The following homeopathic remedies have been historically indicated for symptoms associated with Cystic Fibrosis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 AST to Platelet Ratio Index (APRI) for Hepatitis

Calculates AST to Platelet Ratio Index (APRI) specifically for staging liver fibrosis and cirrhosis in chronic viral hepatitis (Hep B / Hep C) patients.